Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 424

1.
5.

Angiotensin II exerts glucose-dependent effects on Kv currents in mouse pancreatic beta-cells via angiotensin II type 2 receptors.

Chu KY, Cheng Q, Chen C, Au LS, Seto SW, Tuo Y, Motin L, Kwan YW, Leung PS.

Am J Physiol Cell Physiol. 2010 Feb;298(2):C313-23. doi: 10.1152/ajpcell.00575.2008. Epub 2009 Nov 4.

6.

Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R.

Wang XP, Zhang R, Wu K, Wu L, Dong Y.

Pancreas. 2004 Nov;29(4):264-70.

PMID:
15502641
8.

Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway.

Madec AM, Cassel R, Dubois S, Ducreux S, Vial G, Chauvin MA, Mesnier A, Chikh K, Bosco D, Rieusset J, Van Coppenolle F, Thivolet C.

FASEB J. 2013 Dec;27(12):5122-30. doi: 10.1096/fj.13-234104. Epub 2013 Sep 5.

10.

Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.

Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J.

Diabetes. 2006 Sep;55(9):2470-8.

12.
14.

Molecular analysis of db gene-related pancreatic beta cell dysfunction; evidence for a compensatory mechanism inhibiting development of diabetes in the db gene heterozygote.

Kanda Y, Shimoda M, Tawaramoto K, Hamamoto S, Tatsumi F, Kawasaki F, Hashiramoto M, Nakashima K, Matsuki M, Kaku K.

Endocr J. 2009;56(8):997-1008. Epub 2009 Aug 25.

15.

Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.

J Pharmacol Exp Ther. 2006 Aug;318(2):914-21. Epub 2006 Apr 28.

16.

Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.

Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, Honda K, Suzuki Y, Kawabe Y.

Br J Pharmacol. 2013 Oct;170(3):519-31. doi: 10.1111/bph.12269.

17.

Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.

Harrity T, Farrelly D, Tieman A, Chu C, Kunselman L, Gu L, Ponticiello R, Cap M, Qu F, Shao C, Wang W, Zhang H, Fenderson W, Chen S, Devasthale P, Jeon Y, Seethala R, Yang WP, Ren J, Zhou M, Ryono D, Biller S, Mookhtiar KA, Wetterau J, Gregg R, Cheng PT, Hariharan N.

Diabetes. 2006 Jan;55(1):240-8.

18.

Protection of pancreatic beta-cells: is it feasible?

Bonora E.

Nutr Metab Cardiovasc Dis. 2008 Jan;18(1):74-83. Review.

PMID:
18096375
19.

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.

Wang Q, Brubaker PL.

Diabetologia. 2002 Sep;45(9):1263-73. Epub 2002 Apr 26.

PMID:
12242459
20.

Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.

Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA.

J Gastrointest Surg. 2008 Jan;12(1):57-66. Epub 2007 Nov 17.

PMID:
18026817

Supplemental Content

Support Center